作为新型抗病毒剂的加密及其衍生品的发现
Pan Zhou1, Mingxing Li1, Kangkang Yang1
1State Key Laboratory of Elemento-Organic Chemistry, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin 300071, China.
Journal of agricultural and food chemistry
|June 6, 2025
概括
新的含有阿里法氨基群的密托莱平衍生物对烟草马赛克病毒表现出强大的抗病毒活性. 化合物6k具有显著的疗效,与商业药物相美,并且在农业应用方面具有前景.
科学领域:
- 农业化学品 农业化学品 农业化学品
- 有机化学 有机化学
- 植物病理学 植物病理学
背景情况:
- 亚利法胺在农药研发中被广泛使用.
- 在农业中需要新型抗病毒药物来对抗植物疾病.
- 在此之前,克里普托莱平衍生物尚未被探索其抗病毒性质.
研究的目的:
- 设计和合成新型的加密烯衍生物,其中包括亚利法氨基部分.
- 评估这些衍生品对烟草马赛克病毒 (TMV) 的抗病毒活性.
- 调查抗病毒作用机制并评估现场疗效.
主要方法:
- 合成含有异形氨基基组的密托莱衍生物.
- 生物测试以评估体内TMV的无活化,治愈和保护活动.
- 涉及TMV外衣蛋白聚合和碎片化的机制研究.
- 分子对接分析以预测结合亲和力.
- 实地试验用于对TMV和Rhizoctonia solani的疗效评估.
主要成果:
- 大多数合成衍生品对TMV.表现出活性.
- 化合物6k在500mg/L时显示显著的体内无活化 (57.9%),治愈 (51.7%) 和保护 (49.8%) 对TMV的活性,相当于ningnanmycin.
- 化合物6k促进TMV外衣蛋白的聚合和碎片化,影响病毒组装.
- 分子对接表明6k对目标蛋白质的结合亲和力更强.
- 化合物6f和6aa在体内表现出良好的抗Rhizoctonia solani疗效,剂量为400mg/L.
- 化合物6k在现场试验中显示出良好的对照疗效.
结论:
- 新型的加密胺衍生物与异形氨基部分具有针对TMV的显著抗病毒活性.
- 化合物6k是作为作物保护的抗病毒剂进一步开发的有希望的候选物.
- 这项研究强调了密烯衍生物在控制植物病毒和真菌疾病方面的潜力.
更多相关视频
相关概念视频
Subviral Agents
130
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
130
Retroviruses
12.7K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
463
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
463
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Antiepileptic Drugs: Potassium Channel Activators
291
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
291


